Decitabine treatment also augmented the CTAs MAGE-A1, MAGE-A3 and SP17 expression in MDS (SKM-1) and chronic myeloid leukemia (CML) (K562) cell lines. The gene discussed is MAGEA3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.